Mirati sees more responses for KRAS drug in Keytruda combo as it angles for an edge over Amgen

With a filing for its KRAS inhibitor adagrasib right around the corner, Mirati is building a growing case against Amgen as investors watch with bated breath. Promising data from a tiny subgroup of lung cancer patients treated with an adagrasib combo could whet investors’ appetites just enough, but how will…

...

Click to view original post